SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is the dominant focus, with traders weighing the amended upper-limb data, recent rare-disease discussions and new commercial-launch job postings as possible signs of approval. Optimism and short-squeeze speculation are countered by warnings that hiring is not proof of an FDA outcome and that a CRL remains possible; INOs approval is also cited as a positive read-through, not confirmation for CAPR.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

A steep selloff and fresh lows have put AppLovin under pressure ahead of its earnings report, with traders worried about ad-market weakness, peer results, and a possible further drop if guidance disappoints. Bulls argue the decline has outpaced the companys growth and cash generation, while bears see continued downside and are wary of holding through earnings.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,809.831273 with 281,866,746.118905 in circulation. The last known price of OFFICIAL TRUMP is 1.73532194 USD and is up 9.97 over the last 24 hours. It is currently trading on 744 active market(s) with $259,407,006.57 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

A rebound in the Trump-themed meme coin is prompting short-term pump and short-squeeze speculation, but discussion is dominated by its steep losses and accusations that it is a low-utility pump-and-dump; some traders are buying the dip while others expect further declines.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

A third-party observers claim that POET was featured in Foxconns photonics ecosystem has fueled speculation about the companies collaboration and POETs optical-engine prospects. Traders disagree on how meaningful the display is without company confirmation or commercial orders, and many are looking to upcoming results for evidence of production progress and customer demand.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

TEMs volatility is being debated around Q3 earnings and its AI-enabled oncology and data business, with traders citing expanded pharmaceutical partnerships and reimbursement opportunities as bullish context. Optimists point to elevated short interest and squeeze potential, while skeptics focus on profit-taking, insider sales, valuation, and sharp pullbacks.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs steep selloff and trading near recent lows have focused discussion on the upcoming earnings report and whether the company can announce AI/data-center tenant leases; traders are skeptical about the lack of signed deals, while some expect a rebound if leases materialize. Bitcoins moves also shape sentiment toward the miner, with traders debating whether oversold conditions and heavy short interest could support a bounce.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisks sharp post-earnings selloff despite a strong report and raised outlook is being tied to fears that NAND pricing growth is cooling after Kioxias cautious outlook, alongside broader weakness in chip and AI stocks. Bulls call the drop an overreaction given SanDisks results and demand, while bears argue that fading pricing momentum could signal a peak in the memory cycle.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention after a sharp selloff alongside AI and optical stocks, which traders largely view as sector-wide pressure rather than a confirmed company-specific setback. The debate is whether the decline creates a buying opportunity ahead of earnings or reflects concerns about dilution, customer concentration, and the profitability of AI infrastructure spending.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

JMIAs steep selloff and slide toward 52-week lows have traders debating whether higher fuel and shipping costs, broader risk-off sentiment, or worries about delayed profitability and possible dilution are weighing on the shares; no single new negative operational catalyst is widely identified. Bulls are buying the dip and pointing to improving business metrics and the companys profitability targets, while skeptics want confirmation those targets remain achievable.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

A sharp gold selloff and break of key support have put GLD in focus, with traders pointing to repricing toward higher interest rates and possible liquidation pressure as headwinds. The community is split between expecting further declines and treating the drop as a buying opportunity, while many question golds safe-haven behavior as it falls alongside risk assets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Oversold Conditions For Dyne Therapeutics (DYN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...

Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes

Equity

RBC Capital highlighted differences in how Novartis’ and Dyne’s drugs target transferrin protein, their payloads, and their clinical trial designs.

NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy

The company said on Tuesday that its experimental drug del-desiran failed in a late-stage trial. 

Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling

Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.read more...

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?

Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.

Dyne Therapeutics Stock Tumbles After Hours: Here's Why

Dyne Therapeutics stock fell after hours after pricing an upsized $375M public offering of common stock.read more...

Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock

Dyne Therapeutics announced plans to raise $300 million through a public stock offering on Tuesday.


SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space

Citi reiterated a ‘Sell’ rating on SRPT, citing the expected rise in competition within the Duchenne muscular dystrophy (DMD) exon-skipping market.


DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?

Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?

Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026...

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Dyne Therapeutics Inc

Neutral Sentiment

<ul class="summary-bullets"><li>RBC Capital cut its target to $30 from $35 while keeping an ‘Outperform’ rating, according to The Fly.</li><li>Dyne is developing Z-Basivarsen for myotonic dystrophy type 1.</li><li>On Tuesday, Novartis said its Phase 3 study of Del-Desiran failed to achieve its primary goal in patients with myotonic dystrophy type 1.</li></ul>Shares of Dyne Therapeutics (DYN) extended their sell-off on Wednesday, as Wall Street weighed the risk to its experimental muscle-disease drug following a major Phase 3 setback for Novartis (NVS).At the time of writing, <a href="https://stocktwits.com/symbol/DYN">DYN shares</a> traded 4.2% lower, having crashed more than 16% in the previous session.<h2 class="st-heading-2">Why DYN Stock Tanked</h2>On Tuesday, Novartis <a href="http://stocktwits.com/news-articles/markets/equity/nvs-stock-on-track-for-worst-day-in-over-20-years-after-second-trial-failure-in-a-week-dyn-srpt-slip-in-sympathy/cZtEeAyRJy2">said</a> its Phase 3 study of Del-Desiran failed to achieve its primary goal in patients with myotonic dystrophy type 1 (DM1). The rare genetic disease causes progressive muscle weakness and difficulty relaxing muscles after contraction, and currently has no approved treatment.Dyne is developing Z-Basivarsen for the same disease. Both companies’ studies use video hand opening time (vHOT), which measures how quickly a patient can open their hand after making a tight fist.Novartis’ drug failed to produce a statistically significant improvement on that measure, with Baird raising concerns about whether Dyne could face a similar problem.Dyne has enrolled 71 patients in the registrational expansion portion of its Phase 1/2 Achieve study for Z-Basivarsen. Topline results are expected in the first quarter of 2027.<h2 class="st-heading-2">Wall Street Remains Bullish</h2>Following Novartis’ trial data, Baird lowered its price target on Dyne to $26 from $30 but maintained an ‘Outperform’ rating, saying Novartis’ failure creates a challenging read-through for Dyne. The updated target still represents about 37% upside from current levels.RBC Capital also cut its target to $30 from $35 while keeping an ‘Outperform’ rating, but cautioned against directly applying Novartis’ results to Dyne. The firm pointed to differences in how the drugs target transferrin, their payloads, and their clinical trial designs, which it believes could lead to different outcomes.Morgan Stanley also said Novartis’ failure raises risk but believes Dyne's program still has potential. The brokerage lowered the target to $36 from $45 and maintained an ‘Overweight’ rating.The stock has a 12-month consensus price target of $37.53, while 16 of the 17 analysts covering the stock have rated it a ‘Buy’ and one ‘Sell,’ according to Koyfin.<h2 class="st-heading-2">Retail Says Go Long On DYN</h2>Despite the slump, retail sentiment surrounding DYN on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘extremely high’ message volumes.One user saw the slide in share price as a “long opportunity.”<stembedurl>https://stocktwits.com/CC_Abbott/message/663855724</stembedurl>DYN shares have gained around 5.5% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/cmps-stock-defies-market-selloff-after-compass-pathways-psilocybin-trial-success-pointing-to-2027-launch/cZt7EeeRJzj">CMPS Stock Defies Market Selloff After Compass Pathways Psilocybin Trial Success Pointing To 2027 Launch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of US biotech company Dyne Therapeutics Inc. is displayed on a smartphone in front of abstract background on computer screen. (Photo Illustration by Timon Schneider/SOPA Images/LightRocket via Getty Images)

Novartis AG

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$DYN Dyne Therapeutics (NASDAQ: DYN) is expected to report its Q3 2026 earnings on Wednesday, November 4, 2026, after the market closes, with its conference call scheduled for Thursday, November 5, 2026, at 3:00 PM ET.

Feed

News

Sentiment

Earnings

Fundamentals

Info

DYN Dyne Therapeutics Inc

Fundamentals

Latest DYN News